DelveInsight’s “Non-tuberculous Mycobacterial (NTM) Infections Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-tuberculous Mycobacterial (NTM) Infections market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Non-tuberculous Mycobacterial (NTM) Infections drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-tuberculous Mycobacterial (NTM) Infections treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Non-tuberculous Mycobacterial (NTM) Infections: An Overview
According to the Centers for Disease Control and Prevention (CDC), NTM is also referred to as atypical mycobacteria, mycobacteria other than tuberculosis (MOTT), or environmental mycobacteria. It is a ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy persons and those with compromised immune systems.
NTMs can cause infections in a wide variety of body sites, most commonly the lungs and in the following areas: Skin and soft tissue, device-associated infections, Lymph nodes, Blood, or other usually sterile locations in the body. In NTM disorders, the severity of infection and the disease course can vary greatly from one person to another.
The recurrence rate of NTM infection after antibiotic therapy ranges from 20% to 45%. Patients experiencing relapse/recurrence after being treated with antibiotics are then considered for treatment with surgical interventions.
A diagnosis of non-tuberculous mycobacterial disease is based upon the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests. However, the diagnosis can be challenging because the characteristic signs and symptoms are highly variable and nonspecific.
Non-tuberculous Mycobacterial (NTM) Infections Market Key Facts
-
As per DelveInsight’s estimates, a considerable number of prevalent cases of NTM infections were recorded in Japan, with more than 82,000 cases in 2019.
-
Among the EU5 countries, Germany had the highest prevalent population of NTM infections, followed by France and the UK. On the other hand, Spain had the lowest prevalent population of NTM infections.
-
The most prevalent cases of NTM infections were recorded in the United States.
-
Companies like Insmed Incorporated, Savara, Spero Therapeutics, Revimmune, and Paratek Pharmaceuticals Inc. are coming up with novel therapeutic approaches that can entirely change the treatment landscape of NTM infections. The lack of much effective and efficient product in the market, builds a budding chance for the emerging therapies to be launched, providing a fortuitous opportunity to capture the larger market share.
Non-tuberculous Mycobacterial (NTM) Infections Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Non-tuberculous Mycobacterial (NTM) Infections pipeline therapies. It also thoroughly assesses the Non-tuberculous Mycobacterial (NTM) Infections market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Non-tuberculous Mycobacterial (NTM) Infections drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Non-tuberculous Mycobacterial (NTM) Infections Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Non-tuberculous Mycobacterial (NTM) Infections epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Non-tuberculous Mycobacterial (NTM) Infections epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Non-tuberculous Mycobacterial (NTM) Infections Epidemiology, Segmented as –
-
Total Prevalent Cases of NTM Infections in the 7MM (2019–2032)
-
Diagnosed Prevalent Cases of NTM Infections in the 7MM (2019–2032)
-
Diagnosed Prevalent Cases of NTM Infections by Species in the 7MM (2019–2032)
-
Diagnosed Prevalent Cases of NTM Infections by Severity in the 7 MM (2019–2032)
-
Treatable Population of NTM Infections in the 7MM (2019–2032)
Non-tuberculous Mycobacterial (NTM) Infections Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Non-tuberculous Mycobacterial (NTM) Infections market or expected to be launched during the study period. The analysis covers the Non-tuberculous Mycobacterial (NTM) Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Non-tuberculous Mycobacterial (NTM) Infections drugs based on their sale and market share.
The report also covers the Non-tuberculous Mycobacterial (NTM) Infections pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Non-tuberculous Mycobacterial (NTM) Infections companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Non-tuberculous Mycobacterial (NTM) Infections Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market
Non-tuberculous Mycobacterial (NTM) Infections Therapeutics Analysis
For a long, NTM infections have had no proper cure, but researchers have been actively engaged in finding the cure through research on antibacterial drugs. The American Thoracic Society (ATS) and Infectious Disease Society of America (IDSA) recommend a standard NTM lung disease treatment with antibiotic medications. One hope has risen with the approval of Arikayce in the US.
Generally, NTM infection patients are provided with antibiotics such as azithromycin, ciprofloxacin, minocycline, cefoxitin, and imipenem. Currently, the major treatment options for NTM infections are Oral antibiotics (Azithromycin, Ciprofloxacin, and Minocycline), oral + intravenous antibiotics (Cefoxitin and Imipenem), and inhaled antibiotics for NTMPD-refractory cases.
On Jan. 30, 2024, Microbion Corporation announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections. NTM infections are most commonly found in the lungs; however, skin and soft tissue, indwelling medical devices, lymph nodes, and blood can also harbor NTM infections.
Non-tuberculous Mycobacterial (NTM) Infections Companies Actively Working in the Therapeutics Market Include
-
Insmed Incorporated
-
Red Hill Biopharma
-
Novoteris
-
Savara Inc
-
Beyond Air
And Many Others
Emerging and Marketed Non-tuberculous Mycobacterial (NTM) Infections Therapies Covered in the Report Include:
-
SPR720: Spero Therapeutics
-
Molgramostim: Savara Pharmaceuticals
-
Thiolanox (Nitric Oxide): Mallinckrodt Inc
-
NUZYRA (omadacycline): Paratek Pharmaceuticals Inc
-
CYT 107 (Recombinant human interleukin-7): Revimmune
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-tuberculous Mycobacterial (NTM) Infections Competitive Intelligence Analysis
4. Non-tuberculous Mycobacterial (NTM) Infections Market Overview at a Glance
5. Non-tuberculous Mycobacterial (NTM) Infections Disease Background and Overview
6. Non-tuberculous Mycobacterial (NTM) Infections Patient Journey
7. Non-tuberculous Mycobacterial (NTM) Infections Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Non-tuberculous Mycobacterial (NTM) Infections Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-tuberculous Mycobacterial (NTM) Infections Unmet Needs
10. Key Endpoints of Non-tuberculous Mycobacterial (NTM) Infections Treatment
11. Non-tuberculous Mycobacterial (NTM) Infections Marketed Therapies
12. Non-tuberculous Mycobacterial (NTM) Infections Emerging Drugs and Latest Therapeutic Advances
13. Non-tuberculous Mycobacterial (NTM) Infections Seven Major Market Analysis
14. Attribute Analysis
15. Non-tuberculous Mycobacterial (NTM) Infections Market Outlook (In US, EU5, and Japan)
16. Non-tuberculous Mycobacterial (NTM) Infections Companies Active in the Market
17. Non-tuberculous Mycobacterial (NTM) Infections Access and Reimbursement Overview
18. KOL Views on the Non-tuberculous Mycobacterial (NTM) Infections Market
19. Non-tuberculous Mycobacterial (NTM) Infections Market Drivers
20. Non-tuberculous Mycobacterial (NTM) Infections Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Conductive Hearing Loss Market
“Conductive Hearing Loss Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Conductive Hearing Loss market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Conductive Hearing Loss market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Non-tuberculous Mycobacterial (NTM) Infections Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Estimates DelveInsight | Insmed, Novoteris, Savara, Beyond Air